Hansa Medical Interim report January – June 2015
January – June 2015 in summary Operations Summary Q1 Phase II clinical study of IdeS in highly sensitized patients awaiting kidney transplantation successfully completedCooperation initiated with leading US transplantation expert Dr Stanley Jordan at Cedars-Sinai Medical Center, Los AngelesDevelopment of a new generation of IdeS molecules for repeat dosing initiatedPreliminary application for listing on Nasdaq Stockholm submitted Q2 IdeS Phase II study initiated at Uppsala University Hospital and Karolinska University Hospital. The first patient treated with IdeS was